Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

J&J to Accelerate Ebola Vaccine Development

Don't Miss Out —
Follow us on:
Ebola Outbreak
A doctor of the national public health institute controls the temperature of people at the airport, in Abidjan on August 13, 2014, as part of protective measures against the Ebola virus. Photographer: Sia Kambou/AFP/Getty Images

Sept. 4 (Bloomberg) -- Johnson & Johnson said it will fast-track the development of a new combination vaccine regimen against Ebola amid a race to combat the worst outbreak of the deadly disease on record.

The company will collaborate with Denmark-based biotech company Bavarian Nordic and the National Institute of Allergy and Infectious Diseases, it said in a statement today. They will work toward starting a clinical trial in humans in early 2015.

The Ebola outbreak in Liberia, Guinea, Sierra Leone and Nigeria has sickened more than 3,500 people, killing 1,900, more than all previous outbreaks combined, according to the World Health Organization. The number of cases may exceed 20,000 before the epidemic is controlled, the WHO said.

WHO advisers determined last month that experimental treatments against Ebola are ethical to use to help infected patients. The National Institutes of Health and London-based GlaxoSmithKline Plc are also developing an experimental vaccine, with U.S. scientists set to enroll patients in safety trials.

To contact the reporter on this story: Anjali Cordeiro in Hong Kong at acordeiro2@bloomberg.net

To contact the editors responsible for this story: Anjali Cordeiro at acordeiro2@bloomberg.net Frank Longid

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.